Safety and efficiency of using Omaulizumab in bronchial asthma
https://doi.org/10.21886/2219-8075-2019-10-2-6-12
Abstract
This review reviews the efficacy and safety of omalizumab therapy in bronchial asthma using randomized trials of recent years. Mechanisms of the pathogenesis of bronchial asthma, the effectiveness of the drug and its side effects are discussed in detail. The effectiveness of omalizumab is considered at the following key research points: the need for inhaled glucocorticosteroids, the quality of patients’ life and the frequency of exacerbations. Systematic literature search was carried out on the databases Scopus, Web of Science, MedLine, elibrary and others.
About the Authors
E. A. Strel’tsov
Karaganda Medical University
Kazakhstan
Evgeniy A. Strel’tsov - internal illnesses, intern doctor
Competing Interests: not
Kazakhstan
Evgeniy A. Strel’tsov - internal illnesses, intern doctor
Competing Interests: not
V. S. Demidov
Karaganda Medical University
Kazakhstan
Vladislav S. Demidov - internal illnesses, intern doctor
Competing Interests: not
Kazakhstan
Vladislav S. Demidov - internal illnesses, intern doctor
Competing Interests: not
L. V. Tsoy
Karaganda Medical University
Kazakhstan
Competing Interests: not
Kazakhstan
Lyudmila V. Tsoy - internal illnesses, intern doctor
Competing Interests: not
M. E. Korovina
Karaganda Medical University
Kazakhstan
Competing Interests: not
Kazakhstan
Mariya E. Korovina - internal illnesses, intern doctor
Competing Interests: not
N. M. Razyschikova
Karaganda Medical University
Kazakhstan
Nadezhda M. Razyschikova - internal illnesses, intern doctor
Competing Interests: not
Kazakhstan
Nadezhda M. Razyschikova - internal illnesses, intern doctor
Competing Interests: not
А. E. Karzhauova
Karaganda Medical University
Kazakhstan
Competing Interests: not
Kazakhstan
Asel’ E. Karzhauova - internal illnesses, intern doctor
Competing Interests: not
References
1. Kubo M. Innate and adaptive type 2 immunity in lung allergic inflammation. Immunol Rev. 2017;278(1):162-172. doi: 10.1111/imr.12557
2. Nabih ES, Kamel HF, Kamel TB. Association between CD14 polymorphism (-1145G/A) and childhood bronchial asthma. Biochem Genet. 2016;54:50-60. doi: 10.1007/s10528-015-9699-4
3. Dissanayake S, Jain M, Grothe B, Mciver T, Papi A. An evaluation of comparative treatment effects with high and low dose fluticasone propionate/formoterol combination in asthma. Pulm Pharmacol Ther. 2015;35:19-27. doi: 10.1016/j.pupt.2015.10.001
4. Crocker DD , Kinyota S, Dumitru GG, Ligon CB, Herman EJ, Ferdinands JM et all. Effectiveness of home-based, multitrigger, multicomponent interventions with an environmental focus for reducing asthmamorbidity: a community guide systematic review. Am J Prev Med. 2011;41(2 Suppl 1):S5-32. doi: 10.1016/j.amepre.2011.05.012
5. CDC. Asthma: most recent asthma data. 2017. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/asthma/most_recent_data.htm
6. Patel O, Syamlal G., Wood J, Dodd KE, Mazurek JM. Asthma Mortality Among Persons Aged 15-64 Years, by Industry and Occupation - United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018;67(2):60-65. doi: 10.15585/mmwr.mm6702a2
7. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy.2004;59(5):469-78.
8. Tsai MK, Lin YC, Huang MY, Lee MS, Kuo CH, Kuo PL et all. The effects of asthma medications on reactive oxygen species production in human monocytes. J Asthma. 2017;55(4):345-353. doi: 10.1080/02770903.2017.1339798
9. Kaiser SV, Rodean J, Bekmezian A, Hall M, Shah SS, Ma-hant S, et all. Pediatric Research in Inpatient Settings (PRIS) Network: Rising utilization of inpatient pediatric asthma pathways. J Asthma. 2017;55(2):196-207. doi: 10.1080/02770903.2017.1316392
10. Galli SJ. Mast cells and KIT as potential therapeutic targets in severe asthma. N Engl J Med. 2017;376(20):1983-1984. doi: 10.1056/NEJMe1702653.
11. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15:57-65. doi: 10.1038/nri3786
12. Endo Y, Iwamura C, Kuwahara M, Suzuki A, Sugaya K, Tumes DJ et all. Eomesodermin controls interleukin-5 production in memory T helper 2 cells through inhibition of activity of the transcription factor GATA3. Immunity. 2011;35(5):733-45. doi: 10.1016/j.immuni.2011.08.017.
13. Nakayama T, Hirahara K, Onodera A, Endo Y, Hosokawa H, Shinoda K et all. Th2 cells in health and disease. Annu Rev Immunol. 2017;35:53-84. doi: 10.1146/annurev-immu-nol-051116-052350
14. Hess C, Kemper C. Complement-mediated regulation of metabolism and basic cellular processes. Immunity. 2016;45(2):240-54. doi: 10.1016/j.immuni.2016.08.003.
15. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. J Respir Crit Care Med. 2001;164(8 Pt 2): S1-5.
16. Sutton B J, and Davies AM. Structure and dynamics of IgE-receptor interactions: FceRI and CD23/FceRII. Immunol. Rev. 2015;268(1):222-35. doi: 10.1111/imr.12340
17. Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ. J. 2014;7(1):17. doi: 10.1186/1939-4551-7-17
18. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:S6-S11.
19. Pereira Santos MC, Campos Melo A, Caetano A, Caiado J, Mendes A, Pereira Barbosa M et all. Longitudinal study of the expression of FceRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with omalizumab. Eur Ann Allergy Clin Immunol. 2015;47:38-40.
20. Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y et all. Longterm efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports. 2015;5:8191. doi: 10.1038/srep08191
21. Sattler C, Garcia G, Humbert M. Novel targets of omalizumab in asthma. Curr Opin Pulm Med. 2017;23:56-61.
22. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ, Jr, Cala-troni A et all. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136:1476-1485.
23. Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K et all. Omalizumab reduces cysteinyl leukotriene and 9a,11p-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137:1585-1587.e4.
24. Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res. 2017;9:3-14.
25. Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I et all. Omali-zumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a Randomized Phase III Study. Allergy Asthma Immunol Res. 2016;8:319-328.
26. Kuprys-Lipinska I, Molinska K, Kuna P. The effect of omali-zumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Pneumonol Alergol Pol. 2016;84:232-243.
27. Carr TF, Berdnikovs S, Simon HU, Bochner BS, Rosenwasser LJ. Eosinophilic bioactivities in severe asthma. World Allergy Organ J. 2016;9:21.
28. de Llano LP, Vennera MC, Alvarez FJ, Medina JF, Borderias L, Pellicer C et all. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50:296-301.
29. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C et all. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-con-trol, nonatopic asthma. Chest. 2013;144:411-419.
30. Pillai P, Chan YC, Wu SY, Ohm-Laursen L, Thomas C, Durham SR et all. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48:1593-1601.
31. Chen HC, Huang CD, Chang E, Kuo HP. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulmonary Medicine. 2016;16:3. doi: 10.1186/s12890-015-0156-2
32. Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, Mansur AH et all. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016 ;6(8):e011857. doi: 10.1136/bmjopen-2016-011857
33. Donald DW. Asthma and Therapeutics: Recombinant Therapies in Asthma. Allergy Asthma Clin Immunol. 2005;1(1):34-41. doi: 10.1186/1710-1492-1-1-34
34. Scichilone N, Ventura MT, Bonini M, Braido F, Bucca C, Cam-inati M et all. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy. 2015;13(1):7. doi: 10.1186/s12948-015-0016-x
35. Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M et all. Effects of omalizumab in severe asthmatics across ages: A real life Italian experience. Respir Med. 2016;119:141-149. doi: 10.1016/j.rmed.2016.09.005
36. Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K et all. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106-115. doi: 10.1016/j.alit.2016.06.004
37. Al-Ahmad M, Arifhodzic N, Nurkic J, Maher A, Rodriguez-Bouza T, Al-Ahmed N et all. “Real-life” Efficacy and Safety Aspects of Four-year Omalizumab Treatment for Asthma. Med Princ Pract. 2018. doi: 10.1159/000487482
38. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Metcalfe DD et all. (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120(3):594-601.
39. Di Bona D, Fiorino I, Taurino M, Frisenda F, Minenna E, Pasculli C et all. Long-term «real-life» safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respir Med. 2017;130:55-60. doi: 10.1016/j.rmed.2017.07.013
40. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc Med. 2010;103:98-106. doi:10.1258/jrsm.2009.090348
41. Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K et all. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol Int. 2015;64(4):364-70. doi: 10.1016/j.alit.2015.05.006.
42. Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G et all. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489-1495.e5. doi: 10.1016/j.jaci.2016.07.038.
43. Li J, Kang J, Wang C, Yang J, Wang L, Kottakis I, Humphries M et all. Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study. Allergy Asthma Immunol Res. 2016;8(4):319-28. doi: 10.4168/aair.2016.8.4.319
44. Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fuku-naga A et all. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Allergol Int. 2017:S1323-8930(17)30154-5. doi: 10.1016/j.alit.2017.10.001
Review
For citations:
Strel’tsov E.A., Demidov V.S., Tsoy L.V., Korovina M.E., Razyschikova N.M., Karzhauova А.E. Safety and efficiency of using Omaulizumab in bronchial asthma. Medical Herald of the South of Russia. 2019;10(2):6-12. (In Russ.) https://doi.org/10.21886/2219-8075-2019-10-2-6-12
Views:
3980
Email this article 